Cargando…

Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19

PURPOSE: During a global pandemic, the benefit of routine visits and treatment of patients with cancer must be weighed against the risks to patients, staff, and society. Prostate cancer is one of the most common cancers radiation oncology departments treat, and efficient resource utilization is esse...

Descripción completa

Detalles Bibliográficos
Autores principales: Zaorsky, Nicholas G., Yu, James B., McBride, Sean M., Dess, Robert T., Jackson, William C., Mahal, Brandon A., Chen, Ronald, Choudhury, Ananya, Henry, Ann, Syndikus, Isabel, Mitin, Timur, Tree, Alison, Kishan, Amar U., Spratt, Daniel E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7118610/
https://www.ncbi.nlm.nih.gov/pubmed/32292839
http://dx.doi.org/10.1016/j.adro.2020.03.010
_version_ 1783514596288495616
author Zaorsky, Nicholas G.
Yu, James B.
McBride, Sean M.
Dess, Robert T.
Jackson, William C.
Mahal, Brandon A.
Chen, Ronald
Choudhury, Ananya
Henry, Ann
Syndikus, Isabel
Mitin, Timur
Tree, Alison
Kishan, Amar U.
Spratt, Daniel E.
author_facet Zaorsky, Nicholas G.
Yu, James B.
McBride, Sean M.
Dess, Robert T.
Jackson, William C.
Mahal, Brandon A.
Chen, Ronald
Choudhury, Ananya
Henry, Ann
Syndikus, Isabel
Mitin, Timur
Tree, Alison
Kishan, Amar U.
Spratt, Daniel E.
author_sort Zaorsky, Nicholas G.
collection PubMed
description PURPOSE: During a global pandemic, the benefit of routine visits and treatment of patients with cancer must be weighed against the risks to patients, staff, and society. Prostate cancer is one of the most common cancers radiation oncology departments treat, and efficient resource utilization is essential in the setting of a pandemic. Herein, we aim to establish recommendations and a framework by which to evaluate prostate radiation therapy management decisions. METHODS AND MATERIALS: Radiation oncologists from the United States and the United Kingdom rapidly conducted a systematic review and agreed upon recommendations to safely manage patients with prostate cancer during the COVID-19 pandemic. A RADS framework was created: remote visits, and avoidance, deferment, and shortening of radiation therapy was applied to determine appropriate approaches. RESULTS: Recommendations were provided by the National Comprehensive Cancer Network risk group regarding clinical node-positive, postprostatectomy, oligometastatic, and low-volume M1 disease. Across all prostate cancer stages, telemedicine consultations and return visits were recommended when resources/staff available. Delays in consultations and return visits of between 1 and 6 months were deemed safe based on stage of disease. Treatment can be avoided or delayed until safe for very low, low, and favorable intermediate-risk disease. Unfavorable intermediate-risk, high-risk, clinical node-positive, recurrence postsurgery, oligometastatic, and low-volume M1 disease can receive neoadjuvant hormone therapy for 4 to 6 months as necessary. Ultrahypofractionation is preferred for localized, oligometastatic, and low-volume M1, and moderate hypofractionation is preferred for postprostatectomy and clinical node positive disease. Salvage is preferred to adjuvant radiation. CONCLUSIONS: Resources can be reduced for all identified stages of prostate cancer. The RADS (remote visits, and avoidance, deferment, and shortening of radiation therapy) framework can be applied to other disease sites to help with decision making in a global pandemic.
format Online
Article
Text
id pubmed-7118610
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-71186102020-04-03 Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19 Zaorsky, Nicholas G. Yu, James B. McBride, Sean M. Dess, Robert T. Jackson, William C. Mahal, Brandon A. Chen, Ronald Choudhury, Ananya Henry, Ann Syndikus, Isabel Mitin, Timur Tree, Alison Kishan, Amar U. Spratt, Daniel E. Adv Radiat Oncol Practical considerations during COVID19 – Outcomes, education, and intervention PURPOSE: During a global pandemic, the benefit of routine visits and treatment of patients with cancer must be weighed against the risks to patients, staff, and society. Prostate cancer is one of the most common cancers radiation oncology departments treat, and efficient resource utilization is essential in the setting of a pandemic. Herein, we aim to establish recommendations and a framework by which to evaluate prostate radiation therapy management decisions. METHODS AND MATERIALS: Radiation oncologists from the United States and the United Kingdom rapidly conducted a systematic review and agreed upon recommendations to safely manage patients with prostate cancer during the COVID-19 pandemic. A RADS framework was created: remote visits, and avoidance, deferment, and shortening of radiation therapy was applied to determine appropriate approaches. RESULTS: Recommendations were provided by the National Comprehensive Cancer Network risk group regarding clinical node-positive, postprostatectomy, oligometastatic, and low-volume M1 disease. Across all prostate cancer stages, telemedicine consultations and return visits were recommended when resources/staff available. Delays in consultations and return visits of between 1 and 6 months were deemed safe based on stage of disease. Treatment can be avoided or delayed until safe for very low, low, and favorable intermediate-risk disease. Unfavorable intermediate-risk, high-risk, clinical node-positive, recurrence postsurgery, oligometastatic, and low-volume M1 disease can receive neoadjuvant hormone therapy for 4 to 6 months as necessary. Ultrahypofractionation is preferred for localized, oligometastatic, and low-volume M1, and moderate hypofractionation is preferred for postprostatectomy and clinical node positive disease. Salvage is preferred to adjuvant radiation. CONCLUSIONS: Resources can be reduced for all identified stages of prostate cancer. The RADS (remote visits, and avoidance, deferment, and shortening of radiation therapy) framework can be applied to other disease sites to help with decision making in a global pandemic. Elsevier 2020-04-01 /pmc/articles/PMC7118610/ /pubmed/32292839 http://dx.doi.org/10.1016/j.adro.2020.03.010 Text en © 2020 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Practical considerations during COVID19 – Outcomes, education, and intervention
Zaorsky, Nicholas G.
Yu, James B.
McBride, Sean M.
Dess, Robert T.
Jackson, William C.
Mahal, Brandon A.
Chen, Ronald
Choudhury, Ananya
Henry, Ann
Syndikus, Isabel
Mitin, Timur
Tree, Alison
Kishan, Amar U.
Spratt, Daniel E.
Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19
title Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19
title_full Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19
title_fullStr Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19
title_full_unstemmed Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19
title_short Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19
title_sort prostate cancer radiation therapy recommendations in response to covid-19
topic Practical considerations during COVID19 – Outcomes, education, and intervention
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7118610/
https://www.ncbi.nlm.nih.gov/pubmed/32292839
http://dx.doi.org/10.1016/j.adro.2020.03.010
work_keys_str_mv AT zaorskynicholasg prostatecancerradiationtherapyrecommendationsinresponsetocovid19
AT yujamesb prostatecancerradiationtherapyrecommendationsinresponsetocovid19
AT mcbrideseanm prostatecancerradiationtherapyrecommendationsinresponsetocovid19
AT dessrobertt prostatecancerradiationtherapyrecommendationsinresponsetocovid19
AT jacksonwilliamc prostatecancerradiationtherapyrecommendationsinresponsetocovid19
AT mahalbrandona prostatecancerradiationtherapyrecommendationsinresponsetocovid19
AT chenronald prostatecancerradiationtherapyrecommendationsinresponsetocovid19
AT choudhuryananya prostatecancerradiationtherapyrecommendationsinresponsetocovid19
AT henryann prostatecancerradiationtherapyrecommendationsinresponsetocovid19
AT syndikusisabel prostatecancerradiationtherapyrecommendationsinresponsetocovid19
AT mitintimur prostatecancerradiationtherapyrecommendationsinresponsetocovid19
AT treealison prostatecancerradiationtherapyrecommendationsinresponsetocovid19
AT kishanamaru prostatecancerradiationtherapyrecommendationsinresponsetocovid19
AT sprattdaniele prostatecancerradiationtherapyrecommendationsinresponsetocovid19